Achieve Life Sciences (Achieve Life Sciences) Cash, Cash Equivalents, Marketable Securities : $15.50 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Cash, Cash Equivalents, Marketable Securities?

Achieve Life Sciences's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($25.02 Mil) to Sep. 2023 ($19.87 Mil) but then stayed the same from Sep. 2023 ($19.87 Mil) to Dec. 2023 ($15.50 Mil).

Achieve Life Sciences's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($43.02 Mil) to Dec. 2022 ($24.72 Mil) and declined from Dec. 2022 ($24.72 Mil) to Dec. 2023 ($15.50 Mil).

Achieve Life Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Achieve Life Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Cash, Cash Equivalents, Marketable Securities Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

16.66

35.85

43.02

24.72

15.50

Achieve Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															24.72	16.51	25.02	19.87	15.50

Achieve Life Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Achieve Life Sciences (NAS:ACHV) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Achieve Life Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences (Achieve Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

SP4P:Germany

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Executives

John Bencich	officer: CFO and PFO	2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King	director	91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc	10 percent owner	C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn	10 percent owner	C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc	10 percent owner	2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb	10 percent owner	2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p.	10 percent owner	C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p.	10 percent owner	2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025